Emili Masferrer1, Carla Ferrándiz-Pulido2, Magalí Masferrer-Niubò2, Alfredo Rodríguez-Rodríguez2, Inmaculada Gil2, Antoni Pont2, Octavi Servitje2, Antonio García de Herreros2, Belen Lloveras2, Vicenç García-Patos2, Ramon M Pujol2, Agustí Toll2, Inmaculada Hernández-Muñoz2. 1. Department of Dermatology, Facultat de Medicina, Universitat de Barcelona, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques, Universitat Pompeu Fabra (EM), Barcelona, Spain; Department of Pathology (BL), Hospital del Mar, Parc de Salut Mar, Barcelona, Spain; Department of Dermatology (RMP, AT), Hospital del Mar, Parc de Salut Mar, Barcelona, Spain; Department of Dermatology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (CF-P, VG-P), Barcelona, Spain; Department of Urology, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques (AR-R), Barcelona, Spain; Department of Dermatology, Hospital Universitari de Bellvitge, Institut d'Investigació Biomèdica de Bellvitge (OS), Barcelona, Spain; Institut Hospital del Mar d'Investigacions Mèdiques (AGdH), Barcelona, Spain; Department of Mathematics, Universitad Nacional de Educación a Distancia, Madrid (MM-N), Spain; Department of Dermatology (IG), Hospital Universitari St. Joan de Reus-Universitat Rovira i Virgili de Tarragona, Tarragona, Spain; Department of Urology (AP), Hospital Universitari St. Joan de Reus-Universitat Rovira i Virgili de Tarragona, Tarragona, Spain. Electronic address: emilimasferreriniubo@gmail.com. 2. Department of Dermatology, Facultat de Medicina, Universitat de Barcelona, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques, Universitat Pompeu Fabra (EM), Barcelona, Spain; Department of Pathology (BL), Hospital del Mar, Parc de Salut Mar, Barcelona, Spain; Department of Dermatology (RMP, AT), Hospital del Mar, Parc de Salut Mar, Barcelona, Spain; Department of Dermatology, Hospital Universitari Vall d'Hebron, Universitat Autònoma de Barcelona (CF-P, VG-P), Barcelona, Spain; Department of Urology, Hospital del Mar, Parc de Salut Mar, Institut Hospital del Mar d'Investigacions Mèdiques (AR-R), Barcelona, Spain; Department of Dermatology, Hospital Universitari de Bellvitge, Institut d'Investigació Biomèdica de Bellvitge (OS), Barcelona, Spain; Institut Hospital del Mar d'Investigacions Mèdiques (AGdH), Barcelona, Spain; Department of Mathematics, Universitad Nacional de Educación a Distancia, Madrid (MM-N), Spain; Department of Dermatology (IG), Hospital Universitari St. Joan de Reus-Universitat Rovira i Virgili de Tarragona, Tarragona, Spain; Department of Urology (AP), Hospital Universitari St. Joan de Reus-Universitat Rovira i Virgili de Tarragona, Tarragona, Spain.
Abstract
PURPOSE: Epithelial-to-mesenchymal transition is a phenomenon in epithelial tumors that involves loss of intercellular adhesion, mesenchymal phenotype acquisition and enhanced migratory potential. While the epithelial-to-mesenchymal transition process has been extensively linked to metastatic progression of squamous cell carcinoma, studies of the role of epithelial-to-mesenchymal transition in squamous cell carcinoma containing high risk human papillomaviruses are scarce. Moreover, to our knowledge epithelial-to-mesenchymal transition involvement in human penile squamous cell carcinoma, which can arise through transforming HPV infections or independently of HPV, has not been investigated. We evaluated the presence of epithelial-to-mesenchymal transition markers and their relationship to HPV in penile squamous cell carcinoma. MATERIALS AND METHODS: We assessed the expression of E-cadherin, vimentin and the epithelial-to-mesenchymal transition related transcription factors Twist, Zeb1 and Snail by immunohistochemical staining in 64 penile squamous cell carcinoma cases. HPV was detected by polymerase chain reaction amplification. RESULTS: Simultaneous loss of membranous E-cadherin expression and vimentin over expression were noted in 43.5% of penile squamous cell carcinoma cases. HPV was significantly associated with loss of membranous E-cadherin but not with epithelial-to-mesenchymal transition. Recurrence and mortality rates were significantly higher in cases showing epithelial-to-mesenchymal transition. CONCLUSIONS: Our findings indicate that in penile squamous cell carcinoma epithelial-to-mesenchymal transition is associated with poor prognosis but not with the presence of HPV.
PURPOSE: Epithelial-to-mesenchymal transition is a phenomenon in epithelial tumors that involves loss of intercellular adhesion, mesenchymal phenotype acquisition and enhanced migratory potential. While the epithelial-to-mesenchymal transition process has been extensively linked to metastatic progression of squamous cell carcinoma, studies of the role of epithelial-to-mesenchymal transition in squamous cell carcinoma containing high risk human papillomaviruses are scarce. Moreover, to our knowledge epithelial-to-mesenchymal transition involvement in humanpenile squamous cell carcinoma, which can arise through transforming HPV infections or independently of HPV, has not been investigated. We evaluated the presence of epithelial-to-mesenchymal transition markers and their relationship to HPV in penile squamous cell carcinoma. MATERIALS AND METHODS: We assessed the expression of E-cadherin, vimentin and the epithelial-to-mesenchymal transition related transcription factors Twist, Zeb1 and Snail by immunohistochemical staining in 64 penile squamous cell carcinoma cases. HPV was detected by polymerase chain reaction amplification. RESULTS: Simultaneous loss of membranous E-cadherin expression and vimentin over expression were noted in 43.5% of penile squamous cell carcinoma cases. HPV was significantly associated with loss of membranous E-cadherin but not with epithelial-to-mesenchymal transition. Recurrence and mortality rates were significantly higher in cases showing epithelial-to-mesenchymal transition. CONCLUSIONS: Our findings indicate that in penile squamous cell carcinoma epithelial-to-mesenchymal transition is associated with poor prognosis but not with the presence of HPV.
Authors: Ran Xu; Xuan Zhu; Fangzhi Chen; Changkun Huang; Kai Ai; Hongtao Wu; Lei Zhang; Xiaokun Zhao Journal: Cancer Cell Int Date: 2018-03-20 Impact factor: 5.722